LEXG-Lexicon Genetics Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : LEXG-Lexicon Genetics

LXRX 1.390

+3.7%

Oct 31 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: nigel bates who wrote (138)	3/19/2003 4:39:09 PM
From: tuck	of 254

>>THE WOODLANDS, Texas, March 19 /PRNewswire-FirstCall/ -- Lexicon Genetics Incorporated (Nasdaq: LEXG - News) announced today that it has extended its OmniBank® Universal agreement with Boehringer Ingelheim Pharmaceuticals Inc. Under the terms of the agreement, Boehringer Ingelheim will continue its access to Lexicon's OmniBank library through February 2004. Boehringer Ingelheim will also continue to have access to gene knockouts generated under Lexicon's patented gene targeting technologies with genetic alterations directed at specific drug targets of interest, and access to drug target validation data generated by Lexicon for specified targets. Financial terms of the arrangement were not disclosed.<< snip Cheers, Tuck

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next